DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)

Market Cap	20.10B +8.5%
Revenue (ttm)	27.52B +3.1%
Net Income	1.29B +31.8%
EPS	1.13 +30.8%
Shares Out	1.14B
PE Ratio	15.64
Forward PE	14.57
Dividend	0.98 (5.55%)
Ex-Dividend Date	Jun 26, 2026

Volume	8,920,661
Open	17.72
Previous Close	17.65
Day's Range	17.58 - 18.18
52-Week Range	14.39 - 21.78
Beta	0.54
Analysts	Strong Buy
Price Target	24.49 (+35.45%)
Earnings Date	Aug 25, 2026

About SHA:603233

DaShenLin Pharmaceutical Group Co., Ltd. engages in the manufacture, distribution, and retail of pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and tonic herbs, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.

• Industry: Pharmaceutical Retailers
• Sector: Healthcare
• Founded: 1999
• Employees: 41,141
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603233

Financial Performance

In 2025, SHA:603233's revenue was 27.50 billion, an increase of 3.80% compared to the previous year's 26.50 billion. Earnings were 1.24 billion, an increase of 35.04%.

Analyst Summary

According to 10 analysts, the average rating for 603233 stock is "Strong Buy." The 12-month stock price target is ¥24.49, which is an increase of 35.45% from the latest price.

Price Target

¥24.49

(35.45% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 13, 2026

Data Sources Report a data error